Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)

Inclusion Criteria: * Male or female patients aged ≥ 60 years. * Patient with a diagnosis of probable AD * Progressive decline in cognition for more than six months which story is documented in patient medical records * A Mini-Mental State Examination (MMSE) score of 20-26 * With a minimum of educational background * Naïve to anti-dementia treatment * MRI assessment which corroborates the clinical diagnosis (hippocampal atrophy) and excludes other potential causes of dementia especially cerebrovascular lesions * If available, Cerebral Spinal Fluid (CSF) classical biomarkers should be at levels which corroborate the clinical diagnosis * Ambulatory patient living at home with a caregiver available and living in the same household or interacting with the patient daily and available if necessary to ensure administration of the investigational product * Absence of major or severe depressive disease * Patient with a willingness to participate in this study and who have signed an informed consent form Exclusion Criteria: * Early onset of dementia, i.e. before 60 years old to avoid hereditary AD forms * Significant neurological disease other than AD * Major psychiatric disorder or syndrome (schizophrenia or bipolar disorder) * Seizure disorders * Other infectious, metabolic or systemic diseases affecting central nervous system * Other active clinically significant illness * Hospitalization or change of chronic concomitant medications one month prior to screening * Patients with severe respiratory, hepatic or renal failure or with any other significantly potentially disabling abnormality detected during screening * Known hypersensitivity to the tested treatment including active substance and excipients. * Patients participating in another study and exposed to any investigational therapy within the 30 days prior to the entry in this study. * Patient without medical care insurance